Passer au contenu
| Date | Valeur | Objet de la publication | Opinion | Cours | Objectif de cours |
| 16/12/2021 | Capelli | RN S1 2021/22 | Achat | 23€ | 37,1€ (vs 41,4€) |
| 13/12/2021 | Egide | CP | Achat | 1,26€ | 1,85€ (vs 1,74€) |
| 13/12/2021 | Safe | CP | Achat Spec. | 0,32€ | 0,65€ (vs 0,87€) |
| 06/12/2021 | Paulic | CP | Achat | 4,4€ | 7,90€ (vs 8,86€) |
| 02/12/2021 | Invibes | CP | Achat | 19€ | 30,29€ (vs 28,29€) |
| 26/11/2021 | Miliboo | CA S1 2021/22 | Achat | 5,78€ | 8,11€ (vs 9,42€) |
| 25/11/2021 | Capelli | CA S1 2021/22 | Achat | 22,9€ | 37,1€ (vs 41,4€) |
| 19/11/2021 | Adux | CA+EBITDA T3 | Achat | 2,16€ | 3,46€ (vs 3,23€) |
| 19/11/2021 | Paulic | CP | Achat | 5,14€ | 8,86€ (vs 9,10€) |
| 18/11/2021 | Invibes | CP | Achat | 19,3€ | 28,29€ (vs 21,28€) |
| 11/11/2021 | Pharmagest | CA T3 | Achat | 102,4€ | 143,2€ (vs 138,7€) |
| 09/11/2021 | Delta Plus | CA T3 | Neutre | 92,6€ | 100,4€ |
| 04/11/2021 | Sogeclair | CA T3 | Achat | 23€ | 27€ (vs 31€) |
| 03/11/2021 | M2i | CA T3 | Achat | 4,74€ | 8,78€ (vs 7,64€) |
| 03/11/2021 | Prologue | CA T3 | Achat | 0,41€ | 0,74€ (vs 0,70€) |
| 01/11/2021 | Mint | CP | Achat | 5,60€ | 9,28€ |
| 29/10/2021 | Uniti | RN S1 | Achat | 2,14€ | 3,46€ |
| 28/10/2021 | Blockchain Group | RN S1 | Achat | 1,21€ | 2,05€ |
| 28/10/2021 | Adomos | CA+RN S1 | Achat | 0,1544€ | 0,52€ (vs 0,57€) |
| 26/10/2021 | Airwell | CA T3 | Achat | 3,95€ | 5,1€ |
| 19/10/2021 | Reworld Media | CP | Achat | 6,28€ | 10,12€ |
| 15/10/2021 | Paulic Meunerie | RN S1 | Achat | 6,70€ | 9,10€ |
| 14/10/2021 | Invibes | CA T3 | Achat | 16,90€ | 21,28€ (vs 20,85€) |
| 08/10/2021 | Mint | RN S1 | Achat | 6,5€ | 9,28€ (vs 10,15€) |
| 08/10/2021 | Safe Orthopaedics | CA T3 | Achat Spec. | 0,3945€ | 0,87€ |
| 01/10/2021 | M2i | RN S1 | Achat | 4,82€ | 7,64€ |
| 01/10/2021 | Prologue | RN S1 | Achat | 0,4210€ | 0,70€ (vs 0,80€) |
| 01/10/2021 | Safe Orthopaedics | RN S1 | Achat Spec. | 0,4675€ | 0,87€ |
| 30/09/2021 | Invibes | RN S1 | Achat | 18,20€ | 20,85€ (vs 18,25€) |
| 30/09/2021 | Egide | RN S1 | Achat | 1,415€ | 1,74€ |
| 30/09/2021 | Pharmagest | Acquisition | Achat | 95,6€ | 138,7€ |
| 27/09/2021 | Pharmagest | RN S1 | Achat | 98,10€ | 138,7€ |
| 24/09/2021 | Blockchain Group | CP | Achat | 1,224€ | 2,05€ (vs 2,16€) |
| 23/09/2021 | Nextedia | RN S1 | Achat | 1,236€ | 1,65€ |
| 23/09/2021 | Reworld Media | CA+RN S1 | Achat | 4,80€ | 10,12€ (vs 8,31€) |
| 21/09/2021 | Airwell | RN S1 | Achat | 4,1€ | 5,1€ |
| 16/09/2021 | Paulic | CP | Achat | 7,58€ | 9,10€ (vs 11,46€) |
| 10/09/2021 | Miliboo | CA T1 2021/22 | Achat (vs Neutre) | 6,18€ | 9,42€ |
| 09/09/2021 | Sogeclair | RN S1 | Achat | 22,5€ | 31€ |
| 07/09/2021 | Delta Plus | RN S1 | Neutre (vs Achat) | 99,8€ | 100,4€ |
| 02/09/2021 | Airwell | CA S1 | Achat | 4,15€ | 5,1€ (vs 5,4€) |
| 01/09/2021 | Prologue | CP | Achat vs Sous Revue | 0,385€ | 0,80€ (vs Sous Revue) |
| 01/09/2021 | M2i | CP | Achat vs Sous Revue | 4,16€ | 7,63€ (vs Sous Revue) |
| 05/08/2021 | Pharmagest | CA S1 | Achat | 93,5€ | 138,7€ (vs 132,6€) |
| 02/08/2021 | Blockchain Group | CA S1 | Achat | 1,22€ | 2,16€ (vs 2,87€) |
| 02/08/2021 | M2i | CA S1 | Sous Revue | 3,74€ | Sous Revue |
| 02/08/2021 | O2I | CA S1 | Sous Revue | 0,865€ | Sous Revue |
| 02/08/2021 | Prologue | CA S1 | Sous Revue | 0,354€ | Sous Revue |
| 30/07/2021 | Adux | CA+RN S1 | Achat | 1,88€ | 3,23€ (vs 2,70€) |
| 30/07/2021 | Mint | CA S1 | Achat | 8,60€ | 10,15€ (vs 11,23€) |
| 29/07/2021 | Airwell | Initiation | Achat | 3,6€ | 5,4€ |
| 29/07/2021 | Capelli | CA T1 | Achat | 29€ | 41,4€ |
| 29/07/2021 | Delta Plus | CA S1 | Achat | 83,6€ | 100,4€ |
| 26/07/2021 | Egide | CA S1 | Achat | 1,56€ | 1,74€ |
| 22/07/2021 | Nextedia | CA S1 | Achat | 1,15€ | 1,65€ (vs 1,55€) |
| 22/07/2021 | Sogeclair | CA S1 | Achat | 19,15€ | 31€ (vs 30€) |
| 16/07/2021 | Paulic | CA S1 | Achat | 7,60€ | 11,46€ |
| 16/07/2021 | Capelli | RN 2020/21 | Achat | 29€ | 41,4€ |
| 16/07/2021 | Invibes | CA S1 | Achat | 14,50€ | 18,25€ (vs 14,06€) |
| 12/07/2021 | Prologue | Fusion+OPE | Sous Revue vs Achat | 0,399€ | Sous Revue |
| 12/07/2021 | O2i | Fusion | Sous Revue vs Achat | 0,95€ | Sous Revue |
| 12/07/2021 | M2i | OPE | Sous Revue vs Achat | 3,96€ | Sous Revue |
| 09/07/2021 | Adomos | Etude | Achat vs Sous Revue | 0,196€ | 0,57€ |
| 08/07/2021 | Miliboo | RN 2020/21 | Neutre vs Achat | 8,86€ | 9,42€ (vs 9,70€) |
| 08/07/2021 | Safe Orthopaedics | CA S1 2021 | Achat | 0,408€ | 0,88€ |
| 23/06/2021 | Capelli | RN 2020/21 | Achat | 31,2€ | 41,4€ |
| 21/06/2021 | Egide | AG | Achat | 1,475€ | 1,74€ |
| 27/05/2021 | Capelli | CA 2020/21 | Achat | 32,2€ | 41,4€ |
| 27/05/2021 | Miliboo | CA 2020/21 | Achat | 8€ | 9,70€ (vs 8,30€) |
| 13/05/2021 | M2i | CA T1 | Achat | 4,36€ | 6,81€ (vs 6,58€) |
| 13/05/2021 | O2i | CA T1 | Achat | 1,03€ | 1,55€ (vs 1,41€) |
| 13/05/2021 | Pharmagest | CA T1 | Achat | 89,3€ | 132,6€ |
| 13/05/2021 | Prologue | CA T1 | Achat | 0,392€ | 0,95€ (vs 0,83€) |
| 12/05/2021 | Blockchain Group | Initiation | Achat | 1,632€ | 2,87€ |
| 11/05/2021 | Uniti | RN 2020 | Achat (vs Sous Revue) | 2,46€ | 3,46€ (vs Sous Revue) |
| 07/05/2021 | Delta Plus | CA T1 | Achat | 83,6€ | 100,4€ |
| 06/05/2021 | Sogeclair | CA T1 | Achat | 19,7€ | 30€ (vs 28€) |
| 03/05/2021 | Safe Orthopaedics | RN 2020 | Achat | 0,427€ | 0,93€ (vs 0,946€) |
| 29/04/2021 | Invibes | CA T1 | Achat | 11€ | 14,06€ (vs 12,09€) |
| 26/04/2021 | M2i | RN 2020 | Achat | 4,06€ | 6,58€ (vs 5,45€) |
| 26/04/2021 | O2i | RN 2020 | Achat | 1,03€ | 1,41€ (vs 1,37€) |
| 26/04/2021 | Prologue | RN 2020 | Achat | 0,394€ | 0,83€ (vs 0,56€) |
| 23/04/2021 | Mint | RN 2020 | Achat vs Neutre | 9,58€ | 11,23€ (vs 10,80€) |
| 21/04/2021 | Invibes | CP | Achat | 9,70€ | 12,09€ (vs 12,03€) |
| 16/04/2021 | Paulic Meunerie | RN 2020 | Achat | 10,2€ | 11,46€ (vs 10,45€) |
| 13/04/2021 | Delta Plus | RN 2020 | Achat | 81,8€ | 100,4€ (vs 97,2€) |
| 12/04/2021 | Safe Orthopaedics | CA T1 | Achat Spec. | 0,478€ | 0,946€ |
| 02/04/2021 | Adux | RN 2020 | Achat | 1,95€ | 2,70€ |
| 01/04/2021 | Nextedia | RN 2020 | Achat | 1,175€ | 1,55€ |
| 31/03/2021 | Egide | RN 2020 | Achat | 1,18€ | 1,74€ (vs 1,34€) |
| 29/03/2021 | Pharmagest | RN 2020 | Achat | 95,2€ | 132,6€ |
| 26/03/2021 | Adomos | RN 2020 | Sous Revue | 0,312€ | Sous Revue |
| 23/03/2021 | Invibes | RN 2020 | Achat | 9,95€ | 12,01€ (vs 11,22€) |
| 18/03/2021 | Reworld Media | CA+RN 2020 | Achat | 3,64€ | 8,31€ (vs 5,39€) |
| 18/03/2021 | Sogeclair | RN 2020 | Achat | 17,5€ | 28€ (vs 26,9€) |
| 26/02/2021 | Adux | CA+EBITDA 2020 | Achat | 2,42€ | 2,70€ (vs 1,70€) |
| 26/02/2021 | Miliboo | CA T3 2020/21 | Achat | 6,84€ | 8,30€ (vs 5,16€) |
| 12/02/2021 | Delta Plus | CA 2020 | Achat | 84€ | 97,2€ (vs 88,2€) |
| 12/02/2021 | Safe Orthopaedics | CP | Achat Spec. | 0,5719€ | 0,946€ |
| 11/02/2021 | Nextedia | CA 2020 | Achat | 1,38€ | 1,55€ (vs 1,50€) |
| 09/02/2021 | M2i | CA 2020 | Achat | 3,86€ | 5,45€ (vs 5,12€) |
| 09/02/2021 | O2i | CA 2020 | Achat | 1,075€ | 1,37€ (vs 1,27€) |
| 09/02/2021 | Prologue | CA 2020 | Achat | 0,404€ | 0,56€ (vs 0,52€) |
| 05/02/2021 | Pharmagest | CA 2020 | Achat | 118,6€ | 132,6€ (vs 139,4€) |
| 04/02/2021 | Capelli | CA T3 | Achat | 31,8€ | 41,4€ |
| 04/02/2021 | Invibes | CA 2020 | Achat | 8,90€ | 11,22€ (vs 8,76€) |
| 04/02/2021 | Sogeclair | CA 2020 | Achat | 18,20€ | 26,9€ (vs 25€) |
| 02/02/2021 | Adomos | CA 2020 | Sous Revue (vs Achat) | 0,386€ | Sous Revue (vs 0,73€ |
| 02/02/2021 | Delta Plus | Acquisition | Achat | 80€ | 88,2€ (vs 85,8€) |
| 29/01/2021 | Mint | CA 2020 | Neutre | 9,94€ | 10,80€ (vs 10,87€) |
| 27/01/2021 | Mint | CP | Neutre | 9,93€ | 10,87€ |
| 26/01/2021 | Delta Plus | Acquisition | Achat | 75,6€ | 85,8€ (vs 83€) |
| 26/01/2021 | Egide | CA 2020 | Achat | 1,125€ | 1,34€ |
| 22/01/2021 | Paulic | CA 2020 | Achat | 7,90 € | 10,45€ |
| 22/01/2021 | Miliboo | RN S1 2020/21 | Achat | 4,56€ | 5,16€ (vs 4,14€) |
| 15/01/2021 | Safe Orthopaedics | CA 2020 | Neutre | 0,644€ | - |
| 08/01/2021 | Nextedia | Contact | Achat | 1,355€ | 1,50 € (vs 0,74 €) |
| 07/01/2021 | Safe Orthopaedics | CP | Neutre | 0,6719€ | - |
